Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy.
about
Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case reportHIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settingsSingle Nucleotide Polymorphisms in Cellular Drug Transporters Are Associated with Intolerance to Antiretroviral Therapy in Brazilian HIV-1 Positive IndividualsBody Composition and Metabolic Syndrome Components on Lipodystrophy Different Subtypes Associated with HIVAdherence to the Mediterranean diet is associated with a lower risk of body-shape changes in Croatian patients treated with combination antiretroviral therapy.High correlation between Framingham equations with BMI and with lipids to estimate cardiovascular risks score at baseline in HIV-infected adults in the Temprano trial, ANRS 12136 in Côte d'Ivoire.Anthropometric and Nutritional Profile of People Living with HIV and AIDS in India: an AssessmentThe development of simple anthropometric measures to diagnose antiretroviral therapy-associated lipodystrophy in resource limited settingsMagnitude and risk factors of non-communicable diseases among people living with HIV in Tanzania: a cross sectional study from Mbeya and Dar es Salaam regionsGlyceroneogenesis is inhibited through HIV protease inhibitor-induced inflammation in human subcutaneous but not visceral adipose tissue.A longitudinal evaluation of the impact of a polylactic acid injection therapy on health related quality of life amongst HIV patients treated with anti-retroviral agents under real conditions of useHuman lipodystrophies: genetic and acquired diseases of adipose tissue.HIV-associated lipodystrophy: impact of antiretroviral therapy.Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapyAntiretroviral therapies associated with lipoatrophy in HIV-infected womenComparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.Fat distribution in women with HIV infection.Fat distribution in men with HIV infection.The metabolic effects of lopinavir/ritonavir in HIV-negative menThe study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristicsLipid lowering effects of Momordica charantia (Bitter Melon) in HIV-1-protease inhibitor-treated human hepatoma cells, HepG2.New and emerging agents in the management of lipodystrophy in HIV-infected patients.Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.Communication of pharmacogenetic research results to HIV-infected treated patients: standpoints of professionals and patients.HIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact.Leptin in relation to the lipodystrophy-associated metabolic syndromeAtherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population.Posterior intracorneal opacities in patients with HIV infection.Dyslipidemias and Elevated Cardiovascular Risk on Lopinavir-Based Antiretroviral Therapy in CambodiaSafety of lopinavir/ritonavir for the treatment of HIV-infection.HIV-associated lipodystrophy syndrome: A review of clinical aspects.Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors.People living with HIV on ART have accurate perception of lipodystrophy signs: a cross-sectional study.Toxic metabolic syndrome associated with HAART.Increased lipoprotein remnant cholesterol levels in HIV-positive patients during antiretroviral therapy.Minocycline- and tetracycline-induced hypertriglyceridemia in an HIV-seropositive patient receiving combination antiretroviral therapy.Prevalence and Influencing Factors of Thyroid Dysfunction in HIV-Infected Patients.The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patientsDiabetes and Hypertension among Patients Receiving Antiretroviral Treatment Since 1998 in Senegal: Prevalence and Associated FactorsIndependent associations of insulin resistance with high whole-body intermuscular and low leg subcutaneous adipose tissue distribution in obese HIV-infected women.
P2860
Q24814430-F047404F-F4D1-4105-8E16-D0E9980968E5Q28088839-ECF22889-56F4-42D0-9273-2CCE9685A035Q28554250-8129CDE1-8D54-49C0-8FD7-563F6F85FB70Q33678847-A21C85C7-0391-4269-9852-78A073E89DA4Q33752752-B5241989-5618-4D08-821B-78690403AACEQ33764308-2F39BEF1-6BB7-4B0C-B8C9-729C2C8943DCQ34052126-35FAE188-2629-4A8E-AD14-79CA5D3D9DA2Q34067682-D4AE4276-5D21-4F8F-9E1B-4AE9B9EA60F5Q34168721-5D70AD59-A2B1-46AB-A6CD-47FE22720BABQ34503338-B4B48ABF-95D6-491E-B80D-69B07B57B448Q34593181-DDD4801A-BA8C-46E7-9444-32391B0DF9BAQ34620588-F4706362-0015-421A-BFD3-E108D6D64144Q34655845-9D7F5811-18C4-440C-9E7A-0615C81FA4F9Q35025568-E8A3F551-4085-44DE-B507-AA73FED2408EQ35097650-8B60EF85-7D72-4D71-A5C7-208295FD7C63Q35109483-32FCF229-ED69-4D9B-8F67-A3C746709684Q35194384-EB6644ED-68DE-4601-8385-A6C1D38E0039Q35194387-B0549B05-9F32-46CC-9721-8B4130B11F90Q35194394-168679AE-D36A-44BC-9162-07D857618A33Q35206623-3A00E8E4-1D98-4610-86CE-FC4841D5BF1FQ35546434-0DB0681B-217A-48CD-A809-5C1C4CB6CECBQ35557229-48C59211-E13D-4E0F-820F-F1610DDA9950Q35567828-F942861D-1E21-4D7A-B043-5150791D489BQ35793287-5AD8B47C-FA4D-4DB8-BB3D-710E7ACE980FQ36007239-63FA6A26-AA8A-44D2-83D3-579CFC28E866Q36049195-E8664349-1196-487A-A93A-AD640B193C51Q36070094-93F55FD7-D7D0-4D2F-870A-5FADADD1B389Q36086195-78213C6F-FE52-4B91-AF09-E12DD4BE9DB9Q36118338-4E2C4558-3551-401C-9C6C-B25110198566Q36150530-8DFBD63C-6A30-4058-AEAF-BB0E2B50BBFFQ36171069-7B17A362-534C-4AB9-9260-9A8277BFEA97Q36206201-666FA4DD-AE81-415A-82C0-358DA475A01EQ36249550-CF202AB2-8B2F-4461-9962-518EA457DF40Q36544924-FE1E84CB-25AA-49CF-BC23-87E68DA939A5Q36616941-FF5F056C-68DB-4C1A-9387-7EF66CF669B6Q36714593-9E76F050-8BA3-4A12-85BB-09A0E8F0E1B2Q36864149-2159C142-0B58-40FF-A16B-3474818AAD37Q36993971-B27C74EF-D544-45A2-9AFF-27FFDF14119DQ37156843-B4FC9A38-A460-4648-9823-DA32CC198715Q37161855-9EE2E14B-24C1-4651-9E66-CDC130D5DC89
P2860
Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Factors related to lipodystrop ...... active antiretroviral therapy.
@en
Factors related to lipodystrop ...... active antiretroviral therapy.
@nl
type
label
Factors related to lipodystrop ...... active antiretroviral therapy.
@en
Factors related to lipodystrop ...... active antiretroviral therapy.
@nl
prefLabel
Factors related to lipodystrop ...... active antiretroviral therapy.
@en
Factors related to lipodystrop ...... active antiretroviral therapy.
@nl
P2093
P2860
P356
P1476
Factors related to lipodystrop ...... active antiretroviral therapy.
@en
P2093
Antiprotéases Cohorte (APROCO) Study Group
Arnaud Basdevant
Catherine Leport
Christian Perronne
François Raffi
Jacqueline Capeau
Jean-Marie Ragnaud
Marianne Savès
Willy Rozenbaum
P2860
P304
P356
10.1086/339866
P407
P577
2002-04-22T00:00:00Z